Evidence map›Paper›PMID 38312998›Full record

ArticleGlobal heart2024

Nicotine and Cardiovascular Health: When Poison is Addictive - a WHF Policy Brief.

E Ulysses Dorotheo, Monika Arora, Amitava Banerjee, Eduardo Bianco, Nuan Ping Cheah, Regina Dalmau, Thomas Eissenberg, Koji Hasegawa, Pamela Naidoo, Noreen T Nazir and 6 more

Open access · goldAbstract read
In one paragraph

Article in Global heart, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 23 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 16 institutions in 13 countries.

E Ulysses DorotheoSoutheast Asia Tobacco Control Alliance, Philippines.ORCID 0000-0002-6171-6550
Monika AroraPublic Health Foundation of India, India.ORCID 0000-0001-9987-3933
Amitava BanerjeeUniversity College London, United Kingdom.ORCID 0000-0001-8741-3411
Eduardo BiancoFrank Foundation for International Health, Uruguay.
Nuan Ping CheahHealth Sciences Authority, Singapore.ORCID 0000-0002-2459-0653
Regina DalmauUniversity Hospital la Paz, Madrid, Spain.ORCID 0000-0003-0112-4382
Thomas EissenbergVirginia Commonwealth University, United States.ORCID 0000-0002-8277-5437
Koji HasegawaNational Hospital Organization Kyoto Medical Center, Japan.
Pamela NaidooHeart and Stroke Foundation South Africa, South Africa.ORCID 0000-0003-0326-5322
Noreen T NazirUniversity of Illinois Chicago, United States.
L Kristin NewbyDuke University School of Medicine, United States.ORCID 0000-0002-6394-8187
Nour ObeidatKing Hussein Cancer Center, Jordan.ORCID 0000-0002-2827-6872
Andrii SkipalskyiWorld Health Organization, Ukraine.
Janina StępińskaDepartment of Medical Communication, School of Public Health, Centre of Postgraduate Medical Education, Warsaw, Poland.
Jeffrey WillettAmerican Heart Association, United States.
Yunshu WangWorld Heart Federation, Switzerland.
American Heart Association · USAmrita Institute of Medical Sciences and Research Centre · INDuke University · USHealth Foundation · GBHealth Sciences Authority · SGHeart and Stroke Foundation · CAHospital Universitario La Paz · ESKing Hussein Cancer Center · JOKyoto Medical Center · JPPostgraduate School of Molecular Medicine · PLPublic Health Foundation of India · INSoutheast Asia University · THUniversity of Illinois Chicago · USVirginia Commonwealth University · USWorld Health Organization - Pakistan · PKWorld Heart Federation · CH

Funding

World Health Organization 001
6 · The paper itself

Abstract

Nicotine is universally recognized as the primary addictive substance fuelling the continued use of tobacco products, which are responsible for over 8 million deaths annually. In recent years, the popularity of newer recreational nicotine products has surged drastically in many countries, raising health and safety concerns. For decades, the tobacco industry has promoted the myth that nicotine is as harmless as caffeine. Nonetheless, evidence shows that nicotine is far from innocuous, even on its own. In fact, numerous studies have demonstrated that nicotine can harm multiple organs, including the respiratory and cardiovascular systems. Tobacco and recreational nicotine products are commercialized in various types and forms, delivering varying levels of nicotine along with other toxic compounds. These products deliver nicotine in profiles that can initiate and perpetuate addiction, especially in young populations. Notably, some electronic nicotine delivery systems (ENDS) and heated tobacco products (HTP) can deliver concentrations of nicotine that are comparable to those of traditional cigarettes. Despite being regularly advertised as such, ENDS and HTP have demonstrated limited effectiveness as tobacco cessation aids in real-world settings. Furthermore, ENDS have also been associated with an increased risk of cardiovascular disease. In contrast, nicotine replacement therapies (NRT) are proven to be safe and effective medications for tobacco cessation. NRTs are designed to release nicotine in a slow and controlled manner, thereby minimizing the potential for abuse. Moreover, the long-term safety of NRTs has been extensively studied and documented. The vast majority of tobacco and nicotine products available in the market currently contain nicotine derived from tobacco leaves. However, advancements in the chemical synthesis of nicotine have introduced an economically viable alternative source. The tobacco industry has been exploiting synthetic nicotine to circumvent existing tobacco control laws and regulations. The emergence of newer tobacco and recreational nicotine products, along with synthetic nicotine, pose a tangible threat to established tobacco control policies. Nicotine regulations need to be responsive to address these evolving challenges. As such, governments should regulate all tobacco and non-medical nicotine products through a global, comprehensive, and consistent approach in order to safeguard tobacco control progress in past decades.

Indexed as

Cardiovascular SystemPoisonsSmoking CessationHumansNicotinePolicySmokingTobacco ProductsTobacco Use Cessation DevicesNicotinePoisonsRisk Factor for Cardiovascular DiseaseTobacco and Nicotine ProductsTobacco Control and Public Health

Identifiers

PMID38312998
PMCPMC10836189
OpenAlexW4391406060

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.